Ralph Zitnik Selected Research

TNFR-Fc fusion protein (etanercept)

02/2007	Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis.
10/2006	Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.
03/2006	Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
03/2006	Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.
03/2006	Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
01/2006	Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
01/2006	Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
07/2005	No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years.
12/2004	Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis.
12/2003	A randomized trial of etanercept as monotherapy for psoriasis.
11/2003	Etanercept as monotherapy in patients with psoriasis.

10	Psoriasis (Pustulosis Palmaris et Plantaris) 02/2007 - 11/2003
1	Fatigue 01/2006
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 07/2005
1	Rheumatoid Arthritis 07/2005

11	TNFR-Fc fusion protein (etanercept)FDA Link 02/2007 - 11/2003